

January 13, 2014



## Oragenics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity

TAMPA, Fla.-- [Oragenics, Inc.](#) (NYSE MKT:OGEN) (the "Company") today announced that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange") has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity.

### About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health in humans and pets. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names [Evora](#) and [ProBiora](#) in more than 13 countries worldwide.

For more information about Oragenics, visit [www.oragenics.com](http://www.oragenics.com). Follow Oragenics on [Facebook](#) and [Twitter](#).

**Safe Harbor Statement:** *Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management's current views with respect to future events and performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in the filings of Intrexon and Oragenics with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.*

### Oragenics Corporate Contact:

Oragenics, Inc.

**John N. Bonfiglio, PhD**, 813-286-7900 x232

Chief Executive Officer

[jboufiglio@oragenics.com](mailto:jboufiglio@oragenics.com)

or

**Investor / Media Contacts:**

The Ruth Group

**Stephanie Carrington / Aaron Estrada, 646-536-7017/7028**

[scarrington@theruthgroup.com](mailto:scarrington@theruthgroup.com) / [aestrada@theruthgroup.com](mailto:aestrada@theruthgroup.com)

Source: Oragenics, Inc.